Acer Therapeutics Inc.
| NASDAQ: ACER | Healthcare / Biotechnology / USA |
| 2.82 | -0.0200 | -0.70% | Vol 24.32K | 1Y Perf 49.50% |
| Apr 23rd, 2021 10:57 DELAYED |
| BID | 2.80 | ASK | 2.82 | ||
| Open | 2.81 | Previous Close | 2.84 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 10.00 | Analyst Rating | Moderate Buy 2.20 | |
| Potential % | 250.88 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Market Cap | 40.35M | Earnings Rating | Sell | |
| Price Range Ratio 52W % | 23.74 | Earnings Date | 13th May 2021 |
Today's Price Range 2.802.86 | 52W Range 1.885.84 | 5 Year PE Ratio Range -4.00-1.90 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 4.41% | ||
| 1 Month | -18.39% | ||
| 3 Months | -22.62% | ||
| 6 Months | 2.16% | ||
| 1 Year | 49.50% | ||
| 3 Years | -85.22% | ||
| 5 Years | -88.57% | ||
| 10 Years | -99.57% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -97.99 | |||
ROE last 12 Months | -162.17 | |||
ROA (5Y Avg) | -106.62 | |||
ROA last 12 Months | -120.50 | |||
ROC (5Y Avg) | -112.30 | |||
ROC last 12 Months | -131.10 | |||
Return on invested Capital Q | -64.08 | |||
Return on invested Capital Y | -166.24 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.30 | ||||
| 4.73 | ||||
| - | ||||
| - | ||||
| -3.30 | ||||
| -1.53 | ||||
| 67.45 | ||||
| 0.57 | ||||
| 33.53M | ||||
| Forward PE | -1.44 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.90 | ||||
| 1.00 | ||||
| 0.01 | ||||
| 0.04 | ||||
| -2 095.50 | ||||
| Leverage Ratio | 1.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.43 | -0.50 | -16.28 |
| Q03 2020 | -0.44 | -0.51 | -15.91 |
| Q02 2020 | -0.38 | -0.56 | -47.37 |
| Q01 2020 | -0.40 | -0.49 | -22.50 |
| Q04 2019 | -0.55 | -0.51 | 7.27 |
| Q03 2019 | -0.55 | -0.52 | 5.45 |
| Q02 2019 | -0.81 | -1.09 | -34.57 |
| Q01 2019 | -0.87 | -0.79 | 9.20 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.41 | 0.00 | - |
| 6/2021 QR | -0.35 | 12.50 | Positive |
| 12/2021 FY | -1.41 | 14.55 | Positive |
| 12/2022 FY | -1.88 | 2.59 | Positive |
| Next Report Date | 13th May 2021 |
| Estimated EPS Next Report | -0.41 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 24.32K |
| Shares Outstanding | 14.31M |
| Trades Count | 101 |
| Dollar Volume | 418.16K |
| Avg. Volume | 1.18M |
| Avg. Weekly Volume | 100.84K |
| Avg. Monthly Volume | 232.55K |
| Avg. Quarterly Volume | 867.06K |
Acer Therapeutics Inc. (NASDAQ: ACER) stock closed at 2.84 per share at the end of the most recent trading day (a 2.16% change compared to the prior day closing price) with a volume of 91.91K shares and market capitalization of 40.35M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people. Acer Therapeutics Inc. CEO is Chris Schelling.
The one-year performance of Acer Therapeutics Inc. stock is 49.5%, while year-to-date (YTD) performance is 8.4%. ACER stock has a five-year performance of -88.57%. Its 52-week range is between 1.88 and 5.84, which gives ACER stock a 52-week price range ratio of 23.74%
Acer Therapeutics Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 4.73, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -120.50%, a ROC of -131.10% and a ROE of -162.17%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Acer Therapeutics Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Acer Therapeutics Inc.’s next earnings report date is 13th May 2021.
The consensus rating of Wall Street analysts for Acer Therapeutics Inc. is Moderate Buy (2.2), with a target price of $10, which is +250.88% compared to the current price. The earnings rating for Acer Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Acer Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Acer Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.92, ATR14 : 0.27, CCI20 : -74.07, Chaikin Money Flow : 0.00, MACD : -0.18, Money Flow Index : 43.11, ROC : -9.27, RSI : 43.05, STOCH (14,3) : 40.00, STOCH RSI : 1.00, UO : 44.47, Williams %R : -60.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Acer Therapeutics Inc. in the last 12-months were: Chris Schelling (Buy at a value of $500 000), Donald R. Joseph (Buy at a value of $49 998), John M. Dunn (Buy at a value of $74 998), Stephen Aselage (Buy at a value of $157 500)
Acer Therapeutics Inc.
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
CEO: Chris Schelling
Telephone: +1 844 902-6100
Address: 300 Washington Street, Newton 02458, MA, US
Number of employees: 18
